BriaCell Therapeutics (BCTX)

Executive Summary

BriaCell Therapeutics Corp. is a clinical-stage immuno-oncology company focused on developing targeted cellular immunotherapies for cancer. Its lead candidate, Bria-IMT (SV-BR-1-GM), is in a pivotal Phase 3 study (NCT06072612) for metastatic breast cancer, evaluating the combination with cyclophosphamide, interferon, and retifanlimab versus physician's choice. The trial is recruiting and expected to complete in 2028. Additionally, BriaCell is advancing Bria-OTS, a personalized off-the-shelf platform, in a Phase 1/2 trial (NCT06471673) that completed enrollment in 2025, with data readout anticipated soon. The company's approach aims to activate patients' immune systems to specifically destroy tumor cells, offering a potential new option for hard-to-treat breast cancers. With a market cap of ~$30 million, BriaCell represents a high-risk, high-reward opportunity pending clinical data.

Upcoming Catalysts (preview)

• Q1 2027Phase 3 Bria-IMT Interim Analysis40% success
• Q3 2026Bria-OTS Phase 1/2 Data Readout50% success